Artesunate, a drug best known for its lifesaving role in malaria treatment, may have a second life as a targeted therapy against hepatocellular carcinoma, the most common primary cancer of the liver. A new study reports that artesunate directly binds to and inhibits glucosylceramidase, or GBA, an enzyme involved in sphingolipid metabolism. By disrupting this metabolic process, the drug triggered a chain of molecular events that damaged mitochond…
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.